Tramadol, an opioid painkiller widely prescribed globally with over 16 million prescriptions in the US alone in 2023, has long been a treatment for moderate to severe chronic pain. For nearly five decades, doctors have relied on it due to a prevailing clinical belief that it carries a lower potential for addiction compared to stronger opioids like oxycodone and fentanyl, earning it a Schedule IV classification by the DEA for its abuse risk.

However, recent research from Denmark challenges these long-held perceptions. A comprehensive analysis of 19 past clinical trials, involving more than 6,500 individuals taking either tramadol or a placebo, concluded that the drug offers only clinically insignificant pain relief. More alarmingly, the study found that tramadol more than doubles the overall odds of experiencing any serious adverse event.

The analysis highlighted a significant increase in the risk of serious side effects, including higher odds of developing chest pain, coronary artery disease (CAD), and congestive heart failure. Other adverse events noted were nausea, dizziness, and constipation. Researchers stated that "Tramadol may have a slight effect on reducing chronic pain (low certainty of evidence) while likely increasing the risk of both serious… and non-serious adverse events," further adding that "The potential harms associated with tramadol use for pain management likely outweigh its limited benefits."

The increase in serious adverse events was primarily driven by a higher proportion of cardiac events, such as myocardial infarction (heart attack), chest pain, and congestive heart failure, and neoplasms (tumors). Patients taking tramadol had 113 percent higher odds of experiencing a serious adverse event compared to those on a placebo.

While no precise data specifically tracks tramadol use in heart patients, demographic analysis strongly indicates a significant overlap. Tramadol is frequently prescribed for chronic pain in older adults, a demographic already at the highest risk for cardiovascular disease. The average age of participants in the analyzed studies was 58 years, placing them squarely in this high-risk group, suggesting that tramadol could act as a triggering or exacerbating factor for underlying cardiac vulnerabilities.

Amidst the ongoing opioid crisis, physicians face a dilemma in balancing the duty to address genuine patient suffering with pressure to curb opioid prescriptions. This new research prompts a critical reevaluation of tramadol's role in pain management. The Danish researchers urged doctors to "reconsider" prescribing tramadol and to substitute it for "safer alternatives," without providing specific recommendations. They emphasized that doctors should explore options such as non-opioid pain relievers, and drug-free therapies like specific physical therapies and cognitive behavioral therapy. The findings of this significant study were published in the BMJ.